Current Biologics on the Market

Biologics target specific cells or proteins of the immune system and are given by injection or IV infusion. The biologic drugs below have been approved by the FDA for treatment of psoriasis and/or psoriatic arthritis (PsA).

Tumor Necrosis Factor-Alpha (TNF-alpha) Inhibitors

Cimzia (certolizumab pegol), Enbrel (etanercept), Humira (adalimumab), Remicade (infliximab), Simponi (golimumab) and Simponi Aria (golimumab) are drugs that block TNF-alpha. TNF-alpha is a cytokine that prompts the body to create inflammation. In psoriasis and psoriatic arthritis, there is excess production of TNF-alpha in the skin or joints. That leads to the rapid growth of skin cells and/or damage to joint tissue. Blocking TNF-alpha production helps stop the inflammatory cycle of psoriatic disease.

Interleukin 12 and 23 (IL-12, IL-23) Inhibitors

Stelara (ustekinumab) works by selectively targeting the proteins, or cytokines, interleukin 12 (IL-12) and interleukin 23 (IL-23). Interleukins 12/23 are associated with psoriatic inflammation.

Interleukin 17 (IL-17) Inhibitors

Cosentyx (secukinumab) works by selectively targeting the protein, or cytokine, interleukin 17 (IL-17). Interleukin 17 is associated with psoriatic inflammation.

T-Cell Inhibitors

Orencia (abatacept) targets T-cells in the immune system. T-cells are a type of white blood cell that is involved in the inflammation in psoriatic disease. Orencia inhibits T-cells from becoming activated to reduce inflammation.

Interleukin 23 (IL-23) Inhibitors

Ilumya (tildrakizumab-asmn), Skyrizi (risankizumab-rzaa) and Tremfya (guselkumab) work by targeting interleukin 23 (IL-23). This cytokine is linked with inflammation in psoriasis and PsA. Ilumya, Skyrizi and Tremfya work to reduce psoriatic symptoms and slow disease progression.

Stay in the Know.

Expert tips, can’t-miss events and the latest news, straight to your inbox.

National Health Council Standards of ExcellenceCharity NavigatorCommunity Health Charities logoTwill Care logo

Copyright © 1996-2022 National Psoriasis Foundation/USA

Duplication, rebroadcast, republication or other use of content appearing on this website is prohibited without written permission of the National Psoriasis Foundation (NPF).

NPF does not endorse or accept any responsibility for the content of external websites.

NPF does not endorse any specific treatments or medications for psoriasis and psoriatic arthritis.

We use cookies to offer you a better experience and analyze our site traffic. By continuing to use this website, you consent to the use of cookies in accordance with our Privacy Policy.